Skip to content
Review

Immune Checkpoint Inhibitor Therapy in COPD-Concomitant Lung Cancer: A Review of Efficacy Outcomes and Mechanistic Insights.

Nov 2026 · Cancer Letters · pp. 218933 · 0 citations · 134 references
Medicine

Abstract

The coexistence of chronic obstructive pulmonary disease (COPD) and lung cancer (LC) presents a complex clinical scenario with distinct pathological interactions. Beyond shared epidemiological and genetic risk factors, COPD reshapes the pulmonary immune microenvironment through reprogrammed immune-cell compartments, aberrant programmed cell death, and epithelial-mesenchymal transition (EMT), fostering an immunologically "hot" but pathologically permissive milieu that simultaneously drives carcinogenesis and influences treatment responsiveness. Recent evidence suggests that COPD may confer an altered immunological microenvironment that paradoxically enhances responsiveness to immune checkpoint inhibitors (ICIs) in patients with LC. This review mainly synthesizes clinical evidence on the efficacy of ICI, currently the most widely used immunotherapy, in LC patients concomitant with COPD and elucidates potential immunological and molecular mechanisms underlying observed clinical benefits, including heightened programmed cell death protein ligand 1 (PD-L1) expression, elevated tumor mutational burden, increased human leukocyte antigen I (HLA-I) expression, enriched tissue-resident memory T cells and mucosal-associated invariant T cells, and a macrophage polarization shift toward a pro-inflammatory phenotype, with benefits appearing largely attributable to patients with mild-to-moderate airflow obstruction. The safety profile of ICIs in this population-exacerbation risk, eosinophilic airway disease, checkpoint inhibitor pneumonitis (CIP), and autoimmune thyroiditis-is appraised, alongside emerging strategies such as lymphocyte-activation gene 3 (LAG-3), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and T cell immunoreceptor with Ig and ITIM domains (TIGIT) blockade and the immunomodulatory potential of COPD medications (inhaled corticosteroids and long-acting β-agonists). Current evidence remains limited by small retrospective cohorts and heterogeneous stratification. Large-scale prospective studies are warranted. This review aims to clarify the prognostic value of concomitant COPD and guide precision therapeutic strategies for this growing comorbid population.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.